FILE PHOTO: A injection pen of Novo Nordisk’s weight-loss drug

FILE PHOTO: A 0.25 mg injection pen of Novo Nordisk’s weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, September 1, 2023. REUTERS/Victoria Klesty/Illustration/File Photo

Post navigation

Previous: Novo valuation surpasses Tesla on experimental obesity drug data

Live Market Pulse

The charting technology is provided by TradingView. Learn how to use theTradingView Stock Screener.

Sign up for our free Bull Bear Daily Newsletter!

Discover new market trends and ideas directly to your inbox.

Search

You may have missed

2026-02-05T094659Z_2_LYNXMPEM1317G_RTROPTP_4_ISRAEL-PALESTINIANS-AID.JPG

Newsletters

UNICEF calls for criminalization of AI content depicting child sex abuse

Bull Bear Daily February 7, 2026 0

Newsletters

US Justice Department casts wide net on Netflix’s business practices in merger probe, WSJ reports

Bull Bear Daily February 7, 2026 0

2026-02-04T155640Z_2_LYNXMPEM1307N_RTROPTP_4_EL-SALVADOR-BITCOIN.JPG

Newsletters

Tether says ‘misconception’ over fundraising plans amid reports of investor pushback

Bull Bear Daily February 7, 2026 0

2026-02-05T162353Z_2_LYNXMPEM14154_RTROPTP_4_NOVO-NORDISK-RESULTS.JPG

Newsletters

Novo Nordisk to take legal action against Hims & Hers for Wegovy compounding

Bull Bear Daily February 6, 2026 0

Home
Privacy Policy
Terms of Service
Disclaimer
Contact Us

Home
Privacy Policy
Terms of Service
Disclaimer
Contact Us